Daniel Spratt, MD, is the chair of the Department of Radiation Oncology at Case Western Reserve University and University Hospitals Cleveland Medical Center. He is renowned for his expertise in treating genitourinary (GU) malignancies, particularly prostate cancer. Dr. Spratt’s contributions to the field include extensive research, leadership roles, and mentorship, positioning him as a leading authority in prostate cancer treatment. ...
Localized Prostate Cancer
Advertisement
Latest News
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
The 17-gene GPS assay can help physicians with clinical management plans for patients with localized PC.
cN1 patients with PCa who undergo initial treatment with RT have worse PCSM outcomes than those treated with RP.
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
Dr. James Sylora shares his career, patient care, and vision for surgical and therapy advancements in community urology.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Advertisement
Advertisement
Trending
Patients underwent treatment with lenvatinib plus everolimus as a second-line therapy.
An analysis of the phase 3 ARASENS study revealed new information on PSA responses and their association with outcomes.
A review analyzed 30 meta-analyses to determine the association between pretreatment NLR and immunotherapy outcomes.
